image-150-64c8cd514b55a.webp

image-151-64c8cd518a917.webp

group-1000002623-64c8cd4f8d576.webp

image-146-64c8cd50567b2.webp

image-147-64c8cd501e463.webp

image-148-64c8cd50b2c5c.webp

image-149-64c8cd50d627e.webp

BBC-Logo.webp

The-Independent-Logo.webp

Featured in

AI biomarkers, built for real-world impact and clinical trials. Meet us at ASCO 2026 | Booth #IH12.

Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025

Qure.ai partners with Microsoft to increase access to its lung cancer detection and management suite in the U.S.

qTrack

Qure.ai won the Social Innovation Award at the Emerging Companies Summit (ECS), held ahead of the first India edition of the Nvidia GPU Tech Conf, in Mumbai on 5th and 6th December 2016. With ECS, NVIDIA aims to recognize startups that are doing remarkable work in the areas of artificial intelligence, virtual reality, autonomous vehicles and robotics. Qure.ai was one of 12 emerging companies using GPU technology, selected to present at the event, and went on to win the social innovation prize, worth $200,000. The award reinforces Qure’s mission to make healthcare accessible and affordable using deep learning.

Qure.ai, a pioneering healthcare technology startup, has been honored with the prestigious Social Innovation Award at the Emerging Companies Summit (ECS), held in Mumbai on 5th and 6th December 2016. The summit, organized by NVIDIA, a global leader in GPU technology, took place ahead of the first India edition of the NVIDIA GPU Technology Conference. This recognition highlights Qure.ai's exceptional work in leveraging artificial intelligence to revolutionize the healthcare industry and make a significant social impact.

The Emerging Companies Summit serves as a platform for NVIDIA to acknowledge and support startups that are pushing the boundaries of innovation in various domains, including artificial intelligence, virtual reality, autonomous vehicles, and robotics. Qure.ai was selected as one of the 12 emerging companies that have demonstrated remarkable potential in harnessing GPU technology to drive transformative change. The selection process itself is a testament to Qure.ai's cutting-edge work and its ability to stand out among a pool of highly competitive startups.

Qure.ai's groundbreaking achievement at the summit culminated in winning the Social Innovation Award, which carried a substantial prize of $200,000. This recognition not only validates the company's technical prowess but also underscores its unwavering commitment to addressing pressing healthcare challenges through the application of deep learning techniques. By leveraging the power of artificial intelligence, Qure.ai aims to make healthcare more accessible and affordable, particularly in underserved communities and developing nations.

The Social Innovation Award is a resounding endorsement of Qure.ai's mission to democratize healthcare by harnessing the potential of AI. The company's innovative solutions are designed to assist healthcare professionals in making accurate and timely diagnoses, streamlining clinical workflows, and ultimately improving patient outcomes. By automating the analysis of medical images, such as X-rays and CT scans, Qure.ai's technology enables faster and more precise detection of various diseases, including tuberculosis, lung cancer, and brain injuries.

The impact of Qure.ai's work extends beyond the realm of technology, as it has the potential to bridge the healthcare gap in regions where access to quality medical care is limited. By empowering healthcare providers with AI-driven tools, Qure.ai is working towards ensuring that patients, regardless of their socioeconomic background, can receive accurate diagnoses and timely treatment. This aligns perfectly with the company's vision of creating a more equitable and efficient healthcare system.

Moreover, the recognition at the Emerging Companies Summit provides Qure.ai with a platform to showcase its innovative solutions to a wider audience, including industry leaders, investors, and potential collaborators. The event, attended by prominent figures in the technology and healthcare sectors, offers an excellent opportunity for Qure.ai to forge partnerships and attract investments that can further accelerate its growth and impact.

The $200,000 prize that accompanies the Social Innovation Award will undoubtedly provide a significant boost to Qure.ai's research and development efforts. This financial support will enable the company to expand its team, refine its algorithms, and explore new applications of its technology. By investing in cutting-edge research and continuously pushing the boundaries of AI in healthcare, Qure.ai is well-positioned to make a lasting impact on the industry and improve the lives of countless individuals.

Qure.ai's triumph at the Emerging Companies Summit, winning the Social Innovation Award, is a remarkable achievement that highlights the company's dedication to leveraging artificial intelligence for the betterment of healthcare. This recognition not only validates Qure.ai's technical expertise but also underscores its commitment to making a meaningful social impact by democratizing access to quality healthcare. As Qure.ai continues to innovate and expand its reach, the company is poised to play a pivotal role in shaping the future of healthcare, making it more accessible, affordable, and effective for people around the world.

small_71.webp

thumbnail_71.webp

71.webp

Qure.ai wins Nvidia’s Social Innovation Award

Qure.ai won the Segmentation of Cell Nuclei digital pathology challenge at MICCAI 2016. It involved nuclei segmentation in whole slide tissue images obtained from patients with non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioblastoma multiforme (GBM), and lower grade glioma. Qure.ai presented the work at MICCAI conference held at Athens

Qure.ai, a leading provider of artificial intelligence solutions for healthcare, has achieved a significant milestone by winning the Segmentation of Cell Nuclei digital pathology challenge at the prestigious Medical Image Computing and Computer-Assisted Intervention (MICCAI) conference in 2016. This outstanding accomplishment showcases Qure.ai's expertise in developing cutting-edge AI algorithms for medical image analysis and underscores the company's commitment to advancing the field of digital pathology.

The challenge, which was held as part of the MICCAI conference in Athens, Greece, focused on the segmentation of cell nuclei in whole slide tissue images obtained from patients diagnosed with various types of cancer, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioblastoma multiforme (GBM), and lower grade glioma. Accurate segmentation of cell nuclei is crucial for the quantitative analysis of tissue morphology and plays a vital role in cancer diagnosis, prognosis, and treatment planning.

Qure.ai's winning solution demonstrated exceptional performance in accurately segmenting cell nuclei across the diverse range of cancer types included in the challenge. The company's AI algorithm, powered by advanced machine learning techniques and deep learning architectures, was able to effectively handle the complex variations in cell morphology, staining intensity, and tissue heterogeneity that are commonly encountered in digital pathology images.

The success of Qure.ai's algorithm in this challenge highlights the company's expertise in developing robust and generalizable AI solutions that can be applied to a wide range of cancer types and histopathological specimens. By accurately segmenting cell nuclei, Qure.ai's technology enables detailed quantitative analysis of tissue morphology, which can provide valuable insights into tumor biology, progression, and response to therapy.

The implications of Qure.ai's achievement extend beyond the specific challenge and have the potential to revolutionize the practice of digital pathology. By automating the time-consuming and labor-intensive task of cell nuclei segmentation, Qure.ai's AI solution can significantly enhance the efficiency and reproducibility of histopathological analysis. This can lead to faster and more accurate diagnosis, improved patient stratification, and more targeted treatment strategies for cancer patients.

Moreover, the success of Qure.ai's algorithm in this challenge underscores the company's commitment to pushing the boundaries of AI in healthcare and tackling some of the most challenging problems in medical image analysis. By leveraging the power of AI and machine learning, Qure.ai is developing innovative solutions that can augment the capabilities of pathologists and support data-driven decision-making in cancer care.

The recognition of Qure.ai's work at the MICCAI conference in Athens further solidifies the company's position as a leader in the field of AI-powered digital pathology. The conference, which brings together leading researchers, clinicians, and industry experts from around the world, provides an ideal platform for showcasing cutting-edge research and fostering collaborations that can drive the adoption of AI in healthcare.

Qure.ai's victory in the Segmentation of Cell Nuclei digital pathology challenge at MICCAI 2016 is a testament to the company's expertise in developing advanced AI algorithms for medical image analysis. By accurately segmenting cell nuclei across a diverse range of cancer types, Qure.ai's technology has the potential to revolutionize the practice of digital pathology and improve cancer diagnosis, prognosis, and treatment planning. As Qure.ai continues to push the boundaries of AI in healthcare, the company is well-positioned to make significant contributions to the field of digital pathology and improve patient outcomes worldwide.

small_70.webp

thumbnail_70.webp

70.webp

Qure.ai wins Digital Pathology Challenge at MICCAI 2016

Our mission is to use artificial intelligence to make Healthcare more affordable and accessible. Learn more about Qure here.

About Us | Qure AI | Learn more about us here

Join the conversation on AI in healthcare with Qure.ai's blog. Get expert insights, tips, and the latest trends shaping the future of medical technology.

Expert AI Healthcare Blog: Insights, Tips & Trends | Qure.ai

To know more about our AI solutions that are helping provide accessible and affordable healthcare, write to us at partner@qure.ai.

Contact Us | Qure AI

Dive into the world of evidence-based medical AI with Qure.ai. Our research and case studies showcase the effectiveness and advancement of AI in healthcare.

Evidence-Based AI in Medicine: Research & Case Studies | Qure.ai

Qure ai is on a mission to provide accessible, affordable, &amp; timely assistance to healthcare professionals across the globe with the help of AI &amp; deep learning

Qure AI | AI assistance for Accelerated Healthcare

Learn about Qure.ai's impact on healthcare through AI innovations. Read how our solutions are making a difference in patient outcomes globally.

Transforming Healthcare: Our Impact with AI Solutions | Qure.ai

Explore the latest in AI healthcare technology with Qure.ai's insights. Discover how artificial intelligence is improving diagnostics and patient care.

Innovative AI Healthcare Insights & Trends | Qure.ai

Legal Universal Terms Data Processing Agreement Legal Disclaimer Acceptable Use Policy V2.0.0 dt: 30.09.2022 V1.1.0 dt: 30.06.2022 UNIVERSAL TERMS (v2.0.0 dated 30.09.2022) YOUR RELATIONSHIP WITH QURE Your use of Qure’s products, software (including but not limited to any and all versions, forms or renditions of qXR, qER, qCT-Lung, qVH, qMSK qTrack), applications such as the

Legal | Qure AI

Stay updated with the latest news and developments in AI-driven healthcare from Qure.ai. Read about our breakthroughs, events, and industry recognition.

Latest AI Healthcare News & Updates | Qure.ai

Privacy Policy Your privacy is important to us. Privacy Notice Effective Date: 1st September 2022 This Privacy Policy explains how we use the personal information that Qure.ai Technologies Private Limited, its subsidiaries and affiliates collects or generates both in relation to our Website https://qure.ai/ along with any webpages and portals thereof and our mobile application

News and Press